Nucleoside analogs represent the largest class of small molecule-based antivirals, which currently form the backbone of chemotherapy of chronic infections caused by HIV, hepatitis B or C viruses, and herpes viruses. High antiviral potency and favorable pharmacokinetics parameters make some nucleoside analogs suitable also for the treatment of acute infections caused by other medically important RNA and DNA viruses. This review summarizes available information on antiviral research of nucleoside analogs against arthropod-borne members of the genus Flavivirus within the family Flaviviridae, being primarily focused on description of nucleoside inhibitors of flaviviral RNA-dependent RNA polymerase, methyltransferase, and helicase/NTPase. Inhibitors of intracellular nucleoside synthesis and newly discovered nucleoside derivatives with high antiflavivirus potency, whose modes of action are currently not completely understood, have drawn attention. Moreover, this review highlights important challenges and complications in nucleoside analog development and suggests possible strategies to overcome these limitations.

Department of Chemistry and Biochemistry University of Maryland Baltimore USA

Department of Virology Veterinary Research Institute Brno Czech Republic

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Prague Czech Republic

Institute of Parasitology Biology Centre of the Czech Academy of Sciences České Budějovice Czech Republic

Rega Institute for Medical Research KU Leuven Leuven Belgium

See more in PubMed

Baier A. Flaviviral infections and potential targets for antiviral therapy In: Ruzek D. (ed) Flavivirus encephalitis. 1st ed Rijeka: InTech, 2011, pp.89–104.

Lazear HM Stringer EM andde Silva AM.. The emerging zika virus epidemic in the Americas research priorities. J Am Med Assoc 2016; 315: 1945–1946. PubMed

Jeffries CL, Mansfield KL, Phipps LP, et al. Louping ill virus: an endemic tick-borne disease of Great Britain. J Gen Virol 2014; 95: 1005–1014. PubMed PMC

Ashraf U, Ye J, Ruan XD, et al. Usutu virus: an emerging flavivirus in Europe. Viruses 2015; 7: 219–238. PubMed PMC

Rumyantsev AA Murphy BR andPletnev AG.. A tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient mice. J Virol 2006; 80: 1427–1439. PubMed PMC

Blackburn NK andSwanepoel R.. An investigation of flavivirus infections of cattle in Zimbabwe-Rhodesia with particular reference to Wesselsbron virus. J Hyg 1980; 85: 1–33. PubMed PMC

Chambers TJ, Hahn CS, Galler R, et al. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 1990; 44: 649–688. PubMed

Koonin EV. Computer-assisted identification of a putative methyltransferase domain in Ns5 protein of flaviviruses and lambda-2 protein of reovirus. J Gen Virol 1993; 74: 733–740. PubMed

Zhou YS, Ray D, Zhao YW, et al. Structure and function of flavivirus NS5 methyltransferase. J Virol 2007; 81: 3891–3903. PubMed PMC

Wu JQ Liu WC andGong P.. A structural overview of RNA-dependent RNA polymerases from the Flaviviridae family. Int J Mol Sci 2015; 16: 12943–12957. PubMed PMC

Zou G, Chen YL, Dong H, et al. Functional analysis of two cavities in flavivirus NS5 polymerase. J Biol Chem 2011; 286: 14362–14372. PubMed PMC

Deval J Symons JA andBeigelman L.. Inhibition of viral RNA polymerases by nucleoside and nucleotide analogs: therapeutic applications against positive-strand RNA viruses beyond hepatitis C virus. Curr Opin Virol 2014; 9: 1–7. PubMed PMC

Puig-Basagoiti F, Tilgner M, Forshey BM, et al. Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob Agents Chemother 2006; 50: 1320–1329. PubMed PMC

De Clercq E. A 40-year journey in search of selective antiviral chemotherapy. Annu Rev Pharmacol Toxicol 2011; 51: 1–24. PubMed

Jordheim LP, Durantel D, Zoulim F, et al. . Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov 2013; 12: 447–464. PubMed

Benhamou Y Tubiana R andThibault V.. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003; 348: 177–178. PubMed

Ray AS Fordyce MW andHitchcock MJM.. Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus. Antiviral Res 2016; 125: 63–70. PubMed

Huang YS, Chang SY, Sheng WH, et al. Virological response to tenofovir disoproxil fumarate in HIV-positive patients with lamivudine-resistant hepatitis B virus coinfection in an area hyperendemic for hepatitis B virus infection. PLoS One 2016; 11: e0169228. PubMed PMC

Lam YF, Seto WK, Wong D, et al. Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels. Clin Trans Gastroenterol 2017; 8: e125. PubMed PMC

Stedman C. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Ther Adv Gastroenterol 2014; 7: 131–140. PubMed PMC

De Clercq E andHolý A.. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 2005; 4: 928–940. PubMed

Chen YL, Yin Z, Duraiswamy J, et al. Inhibition of dengue virus RNA synthesis by an adenosine nucleoside. Antimicrob Agents Chemother 2010; 54: 2932–2939. PubMed PMC

Eyer L, Nencka R, Huvarova I, et al. Nucleoside inhibitors of zika virus. J Infect Dis 2016; 214: 707–711. PubMed

Eyer L, Valdes JJ, Gil VA, et al. Nucleoside inhibitors of tick-borne encephalitis virus. Antimicrob Agents Chemother 2015; 59: 5483–5493. PubMed PMC

Sacramento CQ, de Melo GR, de Freitas CS, et al. The clinically approved antiviral drug sofosbuvir inhibits zika virus replication. Sci Rep 2017; 7: 40920. PubMed PMC

Yin Z, Chen YL, Schul W, et al. An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci USA 2009; 106: 20435–20439. PubMed PMC

Vernekar SK Qiu L andZacharias J.. Synthesis and antiviral evaluation of 4′-(1,2,3-triazol-1-yl)thymidines. MedChemComm 2014; 5: 603–608.

Vernekar SK, Qiu L, Zhang J, et al. 5′-Silylated 3′-1,2,3-triazolyl thymidine analogues as inhibitors of West Nile Virus and Dengue Virus. J Med Chem 2015; 58: 4016–4028. PubMed PMC

Borowski P, Lang M, Haag A, et al. Characterization of imidazo[4,5-d]pyridazine nucleosides as modulators of unwinding reaction mediated by West Nile virus nucleoside triphosphatase/helicase: evidence for activity on the level of substrate and/or enzyme. Antimicrob Agents Chemother 2002; 46: 1231–1239. PubMed PMC

Borowski P, Deinert J, Schalinski S, et al. Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses. Eur J Biochem 2003; 270: 1645–1653. PubMed

Crance JM, Scaramozzino N, Jouan A, et al. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res 2003; 58: 73–79. PubMed

Leyssen P, Balzarini J, De Clercq E, et al. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of inosine monophosphate dehydrogenase. J Virol 2005; 79: 1943–1947. PubMed PMC

Morrey JD, Smee DF, Sidwell RW, et al. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res 2002; 55: 107–116. PubMed

Ojwang JO, Ali S, Smee DF, et al. Broad-spectrum inhibitor of viruses in the Flaviviridae family. Antiviral Res 2005; 68: 49–55. PubMed

Orlov AA, Drenichev MS, Oslovsky VE, et al. New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors. Bioorg Med Chem Lett 2017; 27: 1267–1273. PubMed

Lescar J andCanard B.. RNA-dependent RNA polymerases from flaviviruses and Picornaviridae. Curr Opin Struct Biol 2009; 19: 759–767. PubMed

Choi KH andRossmann MG.. RNA-dependent RNA polymerases from Flaviviridae. Curr Opin Struct Biol 2009; 19: 746–751. PubMed

Behnam MAM, Nitsche C, Boldescu V, et al. The medicinal chemistry of Dengue virus. J Med Chem 2016; 59: 5622–5649. PubMed

Boldescu V, Behnam MAM, Vasilakis N, et al. Broad-spectrum agents for flaviviral infections: Dengue, Zika and beyond. Nat Rev Drug Discov 2017; 16: 565–586. PubMed PMC

De Clercq E andNeyts J.. Antiviral agents acting as DNA or RNA chain terminators. Handb Exp Pharmacol 2009; 189: 53–84. PubMed

De Clercq E. Antivirals and antiviral strategies. Nat Rev Microbiol 2004; 2: 704–720. PubMed PMC

Cihlar T andRay AS.. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res 2010; 85: 39–58. PubMed

Cho A, Saunders OL, Butler T, et al. Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorg Med Chem Lett 2012; 22: 2705–2707. PubMed PMC

Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016; 531: 381–385. PubMed PMC

Lo MK, Jordan R, Arvey A, et al. GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses. Sci Rep 2017; 7: 43395. PubMed PMC

Eldrup AB, Allerson CR, Bennett CF, et al. Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J Med Chem 2004; 47: 2283–2295. PubMed

Carroll SS, Tomassini JE, Bosserman M, et al. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J Biol Chem 2003; 278: 11979–11984. PubMed

Carroll SS, Koeplinger K, Vavrek M, et al. Antiviral efficacy upon administration of a HepDirect prodrug of 2′-C-methylcytidine to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother 2011; 55: 3854–3860. PubMed PMC

Migliaccio G, Tomassini JE, Carroll SS, et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 2003; 278: 49164–49170. PubMed

Olsen DB, Eldrup AB, Bartholomew L, et al. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob Agents Chemother 2004; 48: 3944–3953. PubMed PMC

Lefebvre DJ, De Vleeschauwer AR, Goris N, et al. Proof of concept for the inhibition of foot-and-mouth disease virus replication by the anti-viral drug 2′-C-methylcytidine in severe combined immunodeficient mice. Transbound Emerg Dis 2014; 61: E89–E91. PubMed

Rocha-Pereira J, Jochmans D, Dallmeier K, et al. Inhibition of norovirus replication by the nucleoside analogue 2′-C-methylcytidine. Biochem Biophys Res Commun 2012; 427: 796–800. PubMed

Rocha-Pereira J, Jochmans D, Debing Y, et al. The viral polymerase inhibitor 2′-C-methylcytidine inhibits Norwalk virus replication and protects against norovirus-induced diarrhea and mortality in a mouse model. J Virol 2013; 87: 11798–11805. PubMed PMC

Eyer L, Smidkova M, Nencka R, et al. Structure-activity relationships of nucleoside analogues for inhibition of tick-borne encephalitis virus. Antiviral Res 2016; 133: 119–129. PubMed

Flint M, McMullan LK, Dodd KA, et al. Inhibitors of the tick-borne, hemorrhagic fever-associated flaviviruses. Antimicrob Agents Chemother 2014; 58: 3206–3216. PubMed PMC

Lee JC, Tseng CK, Wu YH, et al. Characterization of the activity of 2′-C-methylcytidine against dengue virus replication. Antiviral Res 2015; 116: 1–9. PubMed

Mateo R Nagamine CM andKirkegaard K.. Suppression of drug resistance in Dengue virus. MBio 2015; 6: e01960–15. PubMed PMC

Yeo KL, Chen YL, Xu HY, et al. Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors. Antimicrob Agents Chemother 2015; 59: 2086–2093. PubMed PMC

Lanko K, Eggermont K, Patel A, et al. Replication of the Zika virus in different iPSC-derived neuronal cells and implications to assess efficacy of antivirals. Antiviral Res 2017; 145: 82–86. PubMed

Hercik K, Brynda J, Nencka R, et al. Structural basis of Zika virus methyltransferase inhibition by sinefungin. Arch Virol 2017; 162: 2091–2096. PubMed

Eyer L, Kondo H, Zouharova D.et al. Escape of tick-borne flavivirus from 2′ -C-methylated nucleoside antivirals is mediated by a single conservative mutation in NS5 that has a dramatic effect on viral fitness. J Virol 2017; e01028–17. PubMed PMC

Zmurko J, Marques RE, Schols D, et al. The viral polymerase inhibitor 7-deaza-2′-C-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model. PLoS Negl Trop Dis 2016; 10: e0004695. PubMed PMC

Julander JG, Jha AK, Choi JA, et al. Efficacy of 2′-C-methylcytidine against yellow fever virus in cell culture and in a hamster model. Antiviral Res 2010; 86: 261–267. PubMed PMC

Sofia MJ, Chang W, Furman PA, et al. Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase. J Med Chem 2012; 55: 2481–2531. PubMed

Keating GM andVaidya A.. Sofosbuvir: first global approval. Drugs 2014; 74: 273–282. PubMed

Arnold JJ, Sharma SD, Feng JY, et al. Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides. PLoS Pathog 2012; 8: e1003030. PubMed PMC

Feng JY, Xu YL, Barauskas O, et al. Role of mitochondrial RNA polymerase in the toxicity of nucleotide inhibitors of hepatitis C virus. Antimicrob Agents Chemother 2016; 60: 806–817. PubMed PMC

Xu HT, Hassounah SA, Colby-Germinario SP, et al. Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors. J Antimicrob Chemoth 2017; 72: 727–734. PubMed PMC

Bullard-Feibelman KM, Govero J, Zhu Z, et al. The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antiviral Res 2017; 137: 134–140. PubMed PMC

Mumtaz N, Jimmerson LC, Bushman LR, et al. Cell-line dependent antiviral activity of sofosbuvir against Zika virus. Antiviral Res 2017; 146: 161–163. PubMed

Ferreira AC, Zaverucha-do-Valle C, Reis PA, et al. Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae. Sci Rep 2017; 7: 9409. PubMed PMC

Chen YL, Yin Z, Lakshminarayana SB, et al. Inhibition of Dengue Virus by an ester prodrug of an adenosine analog. Antimicrob Agents Chemother 2010; 54: 3255–3261. PubMed PMC

Chen YL Yokokawa F andShi PY.. The search for nucleoside/nucleotide analog inhibitors of dengue virus. Antiviral Res 2015; 122: 12–19. PubMed

Latour DR, Jekle A, Javanbakht H, et al. Biochemical characterization of the inhibition of the dengue virus RNA polymerase by beta-D-2′-ethynyl-7-deaza-adenosine triphosphate. Antiviral Res 2010; 87: 213–222. PubMed

Yin XQ andSchneller SW1.. Deaza-5′-noraisteromycin. Nucleosides Nucleotides Nucleic Acids 2004; 23: 67–76. PubMed

Deng YQ, Zhang NN, Li CF, et al. Adenosine analog NITD008 is a potent inhibitor of Zika virus. Open Forum Infect Dis 2016; 3: ofw175. PubMed PMC

Lo MK, Shi PY, Chen YL, et al. In vitro antiviral activity of adenosine analog NITD008 against tick borne flaviviruses. Antiviral Res 2016; 130: 46–49. PubMed PMC

McGuigan C, Serpi M, Slusarczyk M, et al. Anti-flavivirus activity of different tritylated pyrimidine and purine nucleoside analogues. Chem Open 2016; 5: 227–235. PubMed PMC

Klumpp K, Leveque V, Le Pogam S, et al. The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem 2006; 281: 3793–3799. PubMed

Klumpp K, Kalayanov G, Ma H, et al. Deoxy-4′-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2′-alpha-hydroxyl groups. J Biol Chem 2008; 283: 2167–2175. PubMed

Smith DB, Kalayanov G, Sund C, et al. The design, synthesis, and antiviral activity of 4′-azidocytidine analogues against hepatitis C virus replication: the discovery of 4′-azidoarabinocytidine. J Med Chem 2009; 52: 219–223. PubMed

Hotard AL, He B, Nichol ST, et al. 4′-Azidocytidine (R1479) inhibits henipaviruses and other paramyxoviruses with high potency. Antiviral Res 2017; 144: 147–152. PubMed PMC

Nguyen NM, Tran CNB, Phung LK, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis 2013; 207: 1442–1450. PubMed PMC

Chen YL, Ghafar NA, Karuna R, et al. Activation of peripheral blood mononuclear cells by Dengue virus infection depotentiates balapiravir. J Virol 2014; 88: 1740–1747. PubMed PMC

Rondla R, Coats SJ, McBrayer TR, et al. Anti-hepatitis C virus activity of novel beta-d-2′-C-methyl-4′ -azido pyrimidine nucleoside phosphoramidate prodrugs. Antivir Chem Chemother 2009; 20: 99–106. PubMed PMC

Nilsson M, Kalayanov G, Winqvist A, et al. Discovery of 4′-azido-2′-deoxy-2′-C-methyl cytidine and prodrugs thereof: a potent inhibitor of hepatitis C virus replication. Bioorg Med Chem Lett 2012; 22: 3265–3268. PubMed

Taylor R, Kotian P, Warren T, et al. BCX4430-A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J Infect Public Health 2016; 9: 220–226. PubMed PMC

De Clercq E. C-nucleosides to be revisited. J Med Chem 2016; 59: 2301–2311. PubMed

Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014; 508: 402–405. PubMed PMC

Eyer L, Zouharova D, Sirmarova J, et al. Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses. Antiviral Res 2017; 142: 63–67. PubMed

Julander JG, Siddharthan V, Evans J, et al. Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model. Antiviral Res 2017; 137: 14–22. PubMed PMC

Julander JG, Bantia S, Taubenheim BR, et al. BCX4430, a novel nucleoside analog, effectively treats yellow fever in a hamster model. Antimicrob Agents Chemother 2014; 58: 6607–6614. PubMed PMC

Julander JG, Furuta Y, Shafer K, et al. Activity of T-1106 in a hamster model of yellow fever virus infection. Antimicrob Agents Chemother 2007; 51: 1962–1966. PubMed PMC

Julander JG, Shafer K, Smee DF, et al. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother 2009; 53: 202–209. PubMed PMC

Julander J, Shafer K, Smee D, et al. Efficacy of T-1106 or T-705, alone or in combination with ribavirin, in the treatment of hamsters infected with yellow fever virus. Antiviral Res 2008; 78: A34.

Wu R, Smidansky ED, Oh HS, et al. Synthesis of a 6-methyl-7-deaza analogue of adenosine that potently inhibits replication of polio and Dengue viruses. J Med Chem 2010; 53: 7958–7966. PubMed PMC

Angusti A, Manfredini S, Durini E, et al. Design, synthesis and anti Flaviviridae activity of N-6-, 5′,3′-O- and 5′,2′-O-substituted adenine nucleoside analogs. Chem Pharm Bull 2008; 56: 423–432. PubMed

Morrey JD, Taro BS, Siddharthan V, et al. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res 2008; 80: 377–379. PubMed PMC

Drenichev MS, Oslovsky VE, Sun L, et al. Modification of the length and structure of the linker of N-6-benzyladenosine modulates its selective antiviral activity against enterovirus 71. Eur J Med Chem 2016; 111: 84–94. PubMed

Tararov VI, Tijsma A, Kolyachkina SV, et al. Chemical modification of the plant isoprenoid cytokinin N-6-isopentenyladenosine yields a selective inhibitor of human enterovirus 71 replication. Eur J Med Chem 2015; 90: 406–413. PubMed

Orlov AA, Chistov AA, Kozlovskaya LI, et al. Rigid amphipathic nucleosides suppress reproduction of the tick-borne encephalitis virus. Med Chem Commun 2016; 7: 495–499.

Chatelain G, Debing Y, De Burghgraeve T, et al. In search of flavivirus inhibitors: evaluation of different tritylated nucleoside analogues. Eur J Med Chem 2013; 65: 249–255. PubMed

De Burghgraeve T, Selisko B, Kaptein S, et al. 3′,5′ Di-O-trityluridine inhibits in vitro flavivirus replication. Antiviral Res 2013; 98: 242–247. PubMed

Saudi M, Zmurko J, Kaptein S, et al. In search of flavivirus inhibitors part 2: tritylated, diphenylmethylated and other alkylated nucleoside analogues. Eur J Med Chem 2014; 76: 98–109. PubMed

Koonin EV andDolja VV.. Evolution taxonomy of positive-strand RNA viruses – implications of comparative-analysis of amino-acid-sequences. Crit Rev Biochem Mol Biol 1993; 28: 375–430. PubMed

Cleaves GR andDubin DT.. Methylation status of intracellular dengue type-2 40-S RNA. Virology 1979; 96: 159–165. PubMed

Dong H, Fink K, Zuest R, et al. Flavivirus RNA methylation. J Gen Virol 2014; 95: 763–778. PubMed

Chung KY, Dong HP, Chao AT, et al. Higher catalytic efficiency of N-7-methylation is responsible for processive N-7 and 2′-O methyltransferase activity in dengue virus. Virology 2010; 402: 52–60. PubMed

Lim SP, Wen DY, Yap TL, et al. A scintillation proximity assay for dengue virus NS5 2′-O-methyltransferase-kinetic and inhibition analyses. Antiviral Res 2008; 80: 360–369. PubMed

Lim SP, Sonntag LS, Noble C, et al. Small molecule inhibitors that selectively block dengue virus methyltransferase. J Biol Chem 2011; 286: 6233–6240. PubMed PMC

Chen H, Liu L, Jones SA, et al. Selective inhibition of the West Nile virus methyltransferase by nucleoside analogs. Antiviral Res 2013; 97: 232–239. PubMed PMC

Yates MK, Raje MR, Chatterjee P, et al. Flex-nucleoside analogues – novel therapeutics against filoviruses. Bioorg Med Chem Lett 2017; 27: 2800–2802. PubMed PMC

Peters HL, Jochmans D, de Wilde AH, et al. Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity. Bioorg Med Chem Lett 2015; 25: 2923–2926. PubMed PMC

Seley KL, Zhang L, Hagos A, et al. “ Fleximers”. Design and synthesis of a new class of novel shape-modified nucleosides. J Org Chem 2002; 67: 3365–3373. PubMed

Seley KL, Quirk S, Salim S, et al. Unexpected inhibition of S-adenosyl-L-homocysteine hydrolase by a guanosine nucleoside. Bioorg Med Chem Lett 2003; 13: 1985–1988. PubMed

Quirk S andSeley KL.. Substrate discrimination by the human GTP fucose pyrophosphorylase. Biochemistry 2005; 44: 10854–10863. PubMed

Gallinari P, Brennan D, Nardi C, et al. Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus. J Virol 1998; 72: 6758–6769. PubMed PMC

Hodgman TC. A new superfamily of replicative proteins. Nature 1988; 333: 22–23. PubMed

Kim JL, Morgenstern KA, Griffith JP, et al. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure 1998; 6: 89–100. PubMed

Yao NH, Hesson T, Cable M, et al. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol 1997; 4: 463–467. PubMed

Tai CL, Chi WK, Chen DS, et al. The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3). J Virol 1996; 70: 8477–8484. PubMed PMC

Bretner M, Baier A, Kopańska K, et al. Synthesis and biological activity of 1H-benzotriazole and 1H-benzimidazole analogues – inhibitors of the NTpase/helicase of HCV and of some related Flaviviridae. Antivir Chem Chemother 2005; 16: 315–326. PubMed

Borowski P, Kuehl R, Mueller O, et al. Biochemical properties of a minimal functional domain with ATP-binding activity of the NTPase/helicase of hepatitis C virus. Eur J Biochem 1999; 266: 715–723. PubMed

Borowski P, Lang M, Niebuhr A, et al. Inhibition of the helicase activity of HCV NTPase/helicase by 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide-5′-triphosphate (ribavirin-TP). Acta Biochim Pol 2001; 48: 739–744. PubMed

Borowski P, Mueller O, Niebuhr A, et al. ATP-binding domain of NTPase/helicase as a target for hepatitis C antiviral therapy. Acta Biochim Pol 2000; 47: 173–180. PubMed

Bretner M, Schalinski S, Borowski P, et al. 5′-O-fluorosulfonylbenzoyl esters of purine nucleosides as potential inhibitors of NTPase/helicase and polymerase of Flaviviridae viruses. Nucleosides Nucleotides Nucleic Acids 2003; 22: 1531–1533. PubMed

Bretner M, Schalinski S, Haag A, et al. Synthesis and evaluation of ATP-binding site directed potential inhibitors of nucleoside triphosphatases/helicases and polymerases of hepatitis C and other selected Flaviviridae viruses. Antivir Chem Chemother 2004; 15: 35–42. PubMed

Eriksson B, Helgstrand E, Johansson NG, et al. Inhibition of influenza-virus ribonucleic-acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother 1977; 11: 946–951. PubMed PMC

Crotty S Cameron CE andAndino R.. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA 2001; 98: 6895–6900. PubMed PMC

Graci JD andCameron CE.. Quasispecies, error catastrophe, and the antiviral activity of ribavirin. Virology 2002; 298: 175–180. PubMed

Li CQ, Guillen J, Rabah N, et al. mRNA capping by Venezuelan Equine Encephalitis virus nsP1: functional characterization and implications for antiviral research. J Virol 2015; 89: 8292–8303. PubMed PMC

Graci JD andCameron CE.. Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 2006; 16: 37–48. PubMed PMC

Hultgren C, Milich DR, Weiland O, et al. The antiviral compound ribavirin modulates the T helper (Th)1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998; 79: 2381–2391. PubMed

Jordan I, Briese T, Fischer N, et al. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis 2000; 182: 1214–1217. PubMed

McDowell M, Gonzales SR, Kumarapperuma SC, et al. A novel nucleoside analog, 1-beta-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole (ETAR), exhibits efficacy against a broad range of flaviviruses in vitro. Antiviral Res 2010; 87: 78–80. PubMed PMC

Malinoski FJ, Hasty SE, Ussery MA, et al. Prophylactic ribavirin treatment of dengue type-1 infection in rhesus-monkeys. Antiviral Res 1990; 13: 139–150. PubMed

Gabrielsen B, Phelan MJ, Barthelrosa L, et al. Synthesis and antiviral evaluation of N-carboxamidine-substituted analogs of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride. J Med Chem 1992; 35: 3231–3238. PubMed

Crutcher WA andMoschella SL.. Double-blind controlled crossover high-dose study of azaribine in psoriasis. Br J Dermatol 1975; 92: 199–205. PubMed

Dukhan D, Leroy F, Peyronnet J, et al. Synthesis of 5-aza-7-deazaguanine nucleoside derivatives as potential anti-flavivirus agents. Nucleosides Nucleotides Nucleic Acids 2005; 24: 671–674. PubMed

Korshun VA, Prokhorenko IA, Gontarev SV, et al. New pyrene derivatives for fluorescent labeling of oligonucleotides. Nucleosides Nucleotides 1997; 16: 1461–1464.

Korshun VA, Manasova EV, Balakin KV, et al. New fluorescent nucleoside derivatives – 5-alkynylated 2′-deoxyuridines. Nucleosides Nucleotides 1998; 17: 1809–1812.

Skorobogatyi MV, Malakhov AD, Pchelintseva AA, et al. Fluorescent 5-alkynyl-2′-deoxyuridines: high emission efficiency of a conjugated perylene nucleoside in a DNA duplex. Chembiochem 2006; 7: 810–816. PubMed

St Vincent MR, Colpitts CC, Ustinov AV, et al. Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses. Proc Natl Acad Sci USA 2010; 107: 17339–17344. PubMed PMC

Colpitts CC, Ustinov AV, Epand RF, et al. 5-(Perylen-3-yl) ethynyl-arabino-uridine (aUY11), an arabino-based rigid amphipathic fusion inhibitor, targets virion envelope lipids to inhibit fusion of influenza virus, hepatitis C virus, and other enveloped viruses. J Virol 2013; 87: 3640–3654. PubMed PMC

Vigant F, Hollmann A, Lee J, et al. The rigid amphipathic fusion inhibitor dUY11 acts through photosensitization of viruses. J Virol 2014; 88: 1849–1853. PubMed PMC

Li FJ Maag H andAlfredson T.. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci 2008; 97: 1109–1134. PubMed

Hecker SJ andErion MD.. Prodrugs of phosphates and phosphonates. J Med Chem 2008; 51: 2328–2345. PubMed

Lane AN andFan TWM.. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res 2015; 43: 2466–2485. PubMed PMC

Johnson AA, Ray AS, Hanes J, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001; 276: 40847–40857. PubMed

Lee H Hanes J andJohnson KA.. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 2003; 42: 14711–14719. PubMed PMC

Locarnini S andWarner N.. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV. Antiviral Ther 2007; 12: H15–H23. PubMed

Menendez-Arias L Alvarez M andPacheco B.. Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism, of action and resistance. Curr Opin Virol 2014; 8: 1–9. PubMed

Poveda E, Wyles DL, Mena A, et al. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res 2014; 108: 181–191. PubMed

McGuigan C, Cahard D, Sheeka HM, et al. Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. J Med Chem 1996; 39: 1748–1753. PubMed

Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012; 56: 3359–3368. PubMed PMC

Ross BS, Reddy PG, Zhang HR, et al. Synthesis of diastereomerically pure nucleotide phosphoramidates. J Org Chem 2011; 76: 8311–8319. PubMed

Peterson LW and, McKenna CE. Prodrug approaches to improving the oral absorption of antiviral nucleotide analogues. Expert Opin Drug Deliv 2009; 6: 405–420. PubMed PMC

Becher F, Landman R, Mboup S, et al. Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients. AIDS 2004; 18: 181–187. PubMed

Gao WY, Shirasaka T, Johns DG, et al. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral-blood mononuclear-cells. J Clin Invest 1993; 91: 2326–2333. PubMed PMC

Kohler JJ andLewis W.. A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen 2007; 48: 166–172. PubMed

Maurer HH. Screening procedures for simultaneous detection of several drug classes used for high throughput toxicological analyses and doping control. A review. Comb Chem High Throughput Screen 2000; 3: 467–480. PubMed

Mckim JM. Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with in vivo relevance. Comb Chem High Throughput Screen 2010; 13: 188–206. PubMed PMC

Szymanski P Markowicz M andMikiciuk-Olasik E.. Adaptation of high-throughput screening in drug discovery-toxicological screening tests. Int J Mol Sci 2012; 13: 427–452. PubMed PMC

Adachi A andMiura T.. Animal model studies on viral infections. Front Microbiol 2014; 5: 672. PubMed PMC

Dowall SD, Graham VA, Rayner E, et al. A susceptible mouse model for Zika virus infection. PLoS Negl Trop Dis 2016; 10: e0004658. PubMed PMC

Zompi S andHarris E.. Animal models of Dengue virus infection. Viruses 2012; 4: 62–82. PubMed PMC

Lee YR, Huang KJ, Lei HY, et al. Suckling mice were used to detect infectious dengue-2 viruses by intracerebral injection of the full-length RNA transcript. Intervirology 2005; 48: 161–166. PubMed

Sarathy VV, White M, Li L, et al. A lethal murine infection model for Dengue Virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease. J Virol 2015; 89: 1254–1266. PubMed PMC

Zellweger RM andShresta S.. Mouse models to study dengue virus immunology and pathogenesis. Front Immunol 2014; 5: 151. PubMed PMC

Chan JFW, Zhang AJ, Chan CCS, et al. Zika virus infection in dexamethasone-immunosuppressed mice demonstrating disseminated infection with multi-organ involvement including orchitis effectively treated by recombinant type I interferons. EBioMedicine 2016; 14: 112–122. PubMed PMC

McArthur MA, Suderman MT, Mutebi JP, et al. Molecular characterization of a hamster viscerotropic strain of yellow fever virus. J Virol 2003; 77: 1462–1468. PubMed PMC

Govero J, Esakky P, Scheaffer SM, et al. Zika virus infection damages the testes in mice. Nature 2016; 540: 438–442. PubMed PMC

Gubler D Kuno G andMarkoff L.. Flaviviruses In: Knipe DM andHowley PM (eds) Fields virology. 5th ed Philadelphia, PA: Lippincott Williams & Wilkins, 2007, pp.1153–1253.

Carey I andHarrison PM.. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drug 2009; 18: 1655–1666. PubMed

Wong GLH Wong VWS andChan HLY.. Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B. J Viral Hepat 2014; 21: 825–834. PubMed

Su TH andLiu CJ.. Combination therapy for chronic hepatitis B: current updates and perspectives. Gut Liver 2017; 11: 590–603. PubMed PMC

Synthesis and Biological Profiling of Quinolino-Fused 7-Deazapurine Nucleosides

Synthesis of Polycyclic Hetero-Fused 7-Deazapurine Heterocycles and Nucleosides through C-H Dibenzothiophenation and Negishi Coupling

Synthesis and Anticancer and Antiviral Activities of C-2'-Branched Arabinonucleosides

History of Arbovirus Research in the Czech Republic

Broad-Spectrum Antiviral Activity of 3'-Deoxy-3'-Fluoroadenosine against Emerging Flaviviruses

Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses

An E460D Substitution in the NS5 Protein of Tick-Borne Encephalitis Virus Confers Resistance to the Inhibitor Galidesivir (BCX4430) and Also Attenuates the Virus for Mice

Viral RNA-Dependent RNA Polymerase Inhibitor 7-Deaza-2'-C-Methyladenosine Prevents Death in a Mouse Model of West Nile Virus Infection

Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses